RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Annoroad, a Beijing genetics services company, raised $100 million in a Series C financing, led by SAIF Partners and joined by SBCVC, Shenzhen GTJA Investment Group and Ping An Ventures. Founded in 2012, Annoroad makes non-invasive prenatal diagnostic tests and also assists life science companies in their genetic research. The company has formed partnerships with Illumina for sequencing, Intel for precision medicine and AliCloud, for a cloud-based bioinformatics program called Solar Genomics.
Stock Symbols: (NSDQ: ILMN) (NSDQ: INTC) (NYSE: BABA)
Source: China Biotoday
